Postprandial hyperglycemia and hyperlipidemia-generated glycoxidative stress: Its contribution to the pathogenesis of diabetes complications

European Review for Medical and Pharmacological Sciences

Volumn 9, Issue 4, 2005, Pages 191-208

  Rebolledo, O R ^a   Actis Dato, S M ^a  

^a University of La Plata CONICET   (Argentina)

Author keywords

Diabetic complications; Hyperglycemia; Oxidative stress; Postprandial lipoproteins; Postprandial state

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CARBOHYDRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FREE RADICAL; GLUCOSE; GLUTATHIONE; GLYCERALDEHYDE 3 PHOSPHATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOSYLATED PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) TRANSHYDROGENASE; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYUNSATURATED FATTY ACID; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNINDEXED DRUG; UNSATURATED FATTY ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROGENESIS; AUTOOXIDATION; CARBOHYDRATE METABOLISM; CARBONYLATION; DIABETES MELLITUS; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; ENZYME GLYCOSYLATION; ENZYME SYNTHESIS; GLYCATION; HORMONE INHIBITION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LIPID PEROXIDATION; LIPOPROTEIN METABOLISM; MICROANGIOPATHY; MITOCHONDRIAL RESPIRATION; MOLECULAR MECHANICS; NITRATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; POSTPRANDIAL STATE; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS; FREE RADICALS; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; OXIDATIVE STRESS; POSTPRANDIAL PERIOD;

EID: 23744481257     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Gagliardino JJ. Physiological endocrine control of energy homeostasis and postprandial blood glucose levels. Eur Rev Med Pharmacol Sci 2005; 9: 75-92.
2. American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001; 24: 775-778.
3. Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbA1c Interrelationships in Type 2 diabetes. Diabetes Care 2001; 24: 2023-2029.
4. The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. N Engl J Med 1993; 329: 977-986.
5. United Kingdom Prospective Diabetes Study (UKPDS). Intensive-blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in IDDM. Lancet 1988; 352: 9131.
6. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes: the Steno-2 study. N Engl J Med 2003; 348: 383-393.
7. Heine RJ, Balkau B, Ceriello A, et al. What does postprandial hyperglycaemia mean? Diabet Med 2004; 21: 208-213.
8. Schchiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(Suppl 2): B21-29.
9. Remuzzi A, Viberti GC, Ruggenenti P, et al. Glomerular response to hyperglycemia in human diabetic nephropathy. Am J Physiol 1990; 259: F545-F552.
10. Takeuchi A, Throckmorton DC, Brogden AP, et al. Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 1995; 268: F13-19.
11. Thye-Ronn P, Sindrup SH, Arendt-Nielsen L, et al. Effect of short term hyperglycemia per se on nocioceptive and non-nocioceptive thresholds. Pain 1994; 56: 43-49.
12. Yeap BB, Russo A, Fraser RJ, et al. Hyperglycemia affects cardiovascular autonomic nerve function in normal subjects. Diabetes Care 1996; 19: 880-882.
13. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986; 112: 4322-4337.
14. Ceriello A. The postprandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 125-132.
15. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004; 53: 701-710.
16. Cavallero E, Dachet C, Neufcou D, et al. Postprandial amplification of lipoprotein abnormalities in controlled type II diabetics subjects: relationship to postprandial lipemia and C-peptide/glucagon levels. Metabolism 1994; 43: 270-278.
17. Lundman P, Eriksson M, Schenck-Gustafsson K, et al. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 1997; 96: 3266-3268.
18. Title LM, Cummings PM, Giddens K, et al. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol 2000; 36: 2185-2191.
19. Bae JH, Bassenge E, Kim KB, et al. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidative stress. Atherosclerosis 2001; 155: 517-523.
20. Silveira A, Karpe F, Johnsson H, et al. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb 1996; 16: 1333-1339.
21. Dekker JM, Feskens EJ, Schouten EG, et al. QTc duration is associated with levels of insulin and glucose intolerance. The Zutphen Elderly Study. Diabetes 1996; 45: 376-380.
22. Marfella R, Nappo F, De Angelis L, et al. The effect of acute hyperglycemia on QTc duration in healthy man. Diabetologia 2000; 43: 571-575.
23. Gastaldelli A, Emdin M, Conforti F, et al. Insulin prolongs the QTc interval in humans. Am J Physiol Regul Integr Comp Physiol 2000; 279: R2022-2025.
24. Giugliano D, Marfella R, Coppola L, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783-1790.
25. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
26. American Diabetes Association. Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 2000; 23 (Suppl. 1): S32-42.
27. Ko GTC, Chan JCN, Woo J, et al. Glycated haemoglobin and cardiovascular risk factors in chinese subjects with normal glucose tolerance. Diabet Med 1998; 15: 573-578.
28. Björnholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Diabetes Care 1999; 22: 45-49.
29. Baynes WJ. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405- 412.
30. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257- 267.
31. Rösen P, Nawroth PP, King G, et al. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17: 189-212.
32. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
33. Robertson RP, Harmon J, Tran PO, et al. Glucose toxicity in B-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52: 581-587.
34. Krauss S, Zhang CH, Scorrano L. Superoxide- mediated activation of uncoupling protein 2 causes pancreatic B-dysfunction. J Clin Invest 2003; 112: 1831-1842.
35. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003; 26: 1589-1596.
36. Ceriello A, Mercuri F, Quagliaro L. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001; 44: 834-838.
37. Ceriello A, Quagliaro L, Catone B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002; 25: 1439-1443.
38. Idris I, Gray S, Donnelly R. Protein kinase C activation: isoenzyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001; 44: 659-673.
39. Marfella R, Quagliaro L, Nappo F, et al. Acute hyperglycemia induces an oxidative stress in healthy subjects (Letter). J Clin Invest 2001; 108: 635-636.
40. Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003; 289: 1675-1680.
41. García Soriano F, Virag L, Jagtap P, et al. Diabetic endothelial dysfunction: the role of poly (ADP-ribose) polymerase activation. Nat Med 2001; 7: 108-113.
42. García Soriano F, Pacher P, Mabley J, et al. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly (ADP-ribose) polymerase. Circ Res 2001; 89: 684-691.
43. Szabó C, Zanchi A, Komjáti K, et al. Poly (ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circ Res 2002; 106: 2680-2686.
44. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000; 97: 12222-12226.
45. Beisswenger PJ, Howell SK, O'Dell RM, et al. Alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 2001; 24: 726-732.
46. Kitahara Y, Miura K, Takesue K, et al. Decreased blood excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non obese type 2 diabetes. Metabolism 2002; 51: 1452-1457.
47. Williams B, Gallacher B, Patel H, et al. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth cells in vitro. Diabetes 1997; 46: 1497-1503.
48. Studer RK, Craven PA, Derubertis FR. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes 1993; 42: 118-126.
49. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. Clin Chem 1986; 32: B37- B41.
50. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992; 15: 1835-1842.
51. Wolff SP. The potential role of oxidative stress in diabetes and its complications: novel implications for theory and therapy. In: Diabetic complications: scientific and clinical aspects. Ed Crabbe MJC, New York, Churchill-Livingstone, 1987, pp 167-220.
52. Baynes J, Thorpe S. Role of oxidative stress in diabetic complications. Diabetes 1999; 48: 1-9.
53. Lyons TJ, Jenkins AJ. Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diab Rev 1997; 5: 365-391.
54. Hanefeld M, Kurktchiev T. Plasma lipids in diabetics. In New Horizons in Diabetes Mellitus and Cardiovascular Disease. Ed. CJ Schwartz and GVR Born. London: Current Science 1995, pp 89-95.
55. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81: 18B-25B.
56. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 160-178.
57. Lefêbvre PJ, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diab Med 1998; 15(Suppl 4): S63-68.
58. Patsch JR, Hopferwieser T, Miesenböck G, et al. The relationship of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscl Thromb Vasc Biol 1992; 12: 1336-1345.
59. Ebenbichler CF, Kirchmair R, Egger C, et al. Postprandial state and atherosclerosis. Curr Opin Lipidol 1995; 6: 286-290.
60. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 25-32.
61. Mero N, Syvanne M, Taskinen MR. Post prandial lipid metabolism in diabetes. Atherosclerosis 1998; 141(Suppl 1): S53-S55.
62. Vergès BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999; 25 (Suppl 3): 32-40.
63. Boquist S, Hamsten A, Karpe F, et al. Insulin and non-esterified fatty acid relations to alimentary lipaemia and plasma concentrations of post prandial triglyceride-rich lipoproteins in healthy middle-aged men. Diabetologia 2000; 43: 185-193.
64. Tomkin GH, Owens D. Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 2001; 17: 27-43.
65. Karpe F. Mechanisms of postprandial hyperlipidaemia-remnants and coronary artery disease. Diabet Med 1997; 14 (Suppl 3): S60-S66.
66. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein. EJ Lipid Res 1999; 40: 1-16.
67. Mamo JCL, Proctor SD, Smith D. Retention of chylomicron remnants by arterial tissue: importance of an efficient clearance mechanism from plasma. Atherosclerosis 1998; 141 (Suppl 1): S63-S69.
68. Mann CJ, Yen FT, Grant AM, et al. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991; 88: 2059-2066.
69. Millar JS, Packard CJ. Heterogeneity of apoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies. Curr Opin Lipidol 1998; 9: 197-202.
70. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496.
71. Palinski W, Witztum JL. Oxidative stress and diabetes mellitus. In New Horizons in Diabetes Mellitus and cardiovascular disease. Ed. CJ Schwartz and GVR Born. London: Current Science 1995, p 111-123.
72. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Circulation 2002; 105: 2107-2111.
73. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41: 1481-1494.
74. Navab M, Hama SY, Reddy ST, et al. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol 2002; 13: 363-372.
75. Ceriello A, Bortolotti N, Motz E, et al. Meal induced oxidative stress and low density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 1999; 48: 1503-1508.
76. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Circulation 2002; 106: 1211-1218.
77. Moro E, Alessandrini P, Zambon C, et al. Is glycation of low density lipoproteins in patientes with Type 2 diabetes mellitus a LDL pre-oxidative condition? Diabet Med 1999; 16: 663-669.
78. Sakata N, Uesugi N, Takebayashi S, et al. Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogenesis. Cardiovasc Res 2001; 49: 466-475.
79. Bucala R. Lipid and lipoprotein advanced glycosylation in diabetic cardiovascular disease. In New Horizons in Diabetes Mellitus and cardiovascular disease. Ed. CJ Schwartz and GVR Born. London: Current Science 1995, p 103-110.
80. Ravandi A, Kuksis A, Shaikh NA. Glucosylated Glycerophosphoethanolamines are the major LDL glycation products and increase LDL susceptibility to oxidation. Artherioscler Thromb Vasc Biol 2000; 20: 467-477.
81. Lopes-Virella MF, Klein RL, Virella G. Modification of lipoproteins in diabetes. Diab Metab Rev 1996; 12: 69-90.
82. AACE. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management 2002 update. Endocr Pract 2002; 8 (Suppl 1): 41-82.